Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618718 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL15101461 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL4697949 | 0.96 | HPGD (0.38) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL112479 | 0.91 | GNAI3 (0.44) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL4593370 | 0.89 | GNAI3 (0.47) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| SCHEMBL1421166 | 0.83 | HPGD (0.35) | HPGDKDM1ACPN1CPB2ALDH1A1 | |
| SCHEMBL477321 | 0.83 | HPGD (0.35) | HPGDKDM1ACPN1CPB2ALDH1A1 | |
| SCHEMBL1248249 | 0.83 | HPGD (0.35) | HPGDKDM1ACPN1CPB2ALDH1A1 | |
| SCHEMBL14275857 | 0.81 | EPHX2 (0.46) | CHRM2CHRM1CHRM3GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL3487633 | 0.81 | KDM1A (0.34) | HPGDKDM1ACPN1CPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115991706-A | PIM kinase inhibitors | 杭州邦顺制药有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
| EP-3880679-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021023858-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | UNIVERSITÉ DE STRASBOURG (FR) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020099882-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| EP-2780015-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| CN-103483317-A | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC | 2014-01-01 | — | — | CN | disclosed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009091856-A2 | BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2076487-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-07-08 | — | — | EP | disclosed |
| EP-2057141-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | Pfizer Products Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| CN-101415675-A | 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | ABBOTT LAB (US) | 2009-04-22 | — | — | CN | disclosed |
| EP-2007719-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | Abbott Laboratories (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008049808-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008023239-A1 | PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| WO-2007118185-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | PNLIP, APOB, MTPN | CHRM2 4474/4885CHRM1 4355/4885CHRM3 4652/4885 |
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | CHRM2 1374/4885CHRM1 1285/4885CHRM3 1156/4885 |
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | CHRM2 234/4885CHRM1 180/4885CHRM3 128/4885 |
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | CHRM2 27/4885CHRM1 47/4885CHRM3 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.